DOCSLIB.ORG

1 CURRICULUM VITAE ARMANDO SARDI, M.D., FACS PRESENT POSITION Chief Surgical Oncology Medical Director, Institute for Cancer Ca

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
1 CURRICULUM VITAE ARMANDO SARDI, M.D., FACS PRESENT POSITION Chief Surgical Oncology Medical Director, Institute for Cancer Ca CURRICULUM VITAE ARMANDO SARDI, M.D., FACS PRESENT POSITION Chief Surgical Oncology Medical Director, Institute for Cancer Care Mercy Medical Center, Baltimore, Maryland BUSINESS ADDRESS Institute for Cancer Care at Mercy Division of Surgical Oncology 4th Floor Weinberg Building 227 Saint Paul Place Baltimore, Maryland 21202 (410)-332-9294-OFFICE (410)-332-9731-FAX LANGUAGE Fluent in English Primary Language Spoken: Spanish DEGREES M.D. Universidad del Valle Cali, Colombia - S.A. 1973-1980 POST GRADUATE TRAINING Hospital Santander San Andres Island, Colombia - S.A. 1980-1981 Rural Service* * Required by the Colombian Ministry of Education and Health for all medical graduates of Colombia. INTERNSHIP Universidad del Valle Cali, Colombia - S.A. 1979-1980 Rotating Internship South Baltimore General Hospital Baltimore, Maryland - U.S.A. 1981-1982 Surgical Intern RESIDENCY South Baltimore General Hospital Baltimore, Maryland - U.S.A. 1982-1983 Surgical Resident Saint Agnes Hospital Baltimore, Maryland - U.S.A. 1983-1985 Surgical Resident RESIDENCY Saint Agnes Hospital Baltimore, Maryland - U.S.A. 1985-1986 Surgical Oncology Fellow & Surgical Chief Resident FELLOWSHIP Ohio State University Hospital Division of Surgical Oncology 1 Columbus, Ohio - U.S.A. 1986-1988 American Cancer Society Clinical Fellowship Grant 1987-1988 CERTIFICATIONS American Board of Surgery NIH certified on the Protection of Human Research Subjects (12/2000) HONORS AND AWARDS Full scholarship for occupying first place (1/95) in medical school. March 1974 through February 1975. Full scholarship for attaining/receiving first place (1/92) in medical school. April 1975 through March 1976. Cianos Award - Saint Agnes Hospital. June 1984, (awarded to the surgical resident who has demonstrated more extensive knowledge in basic sciences). Cianos Award - Saint Agnes Hospital. June 1986, (awarded to the surgical resident who has demonstrated more extensive knowledge in basic sciences). First place winner, Ohio Chapter American College of Surgeons Resident Essay Contest, "Localization of tumor labeled with antibody 'cocktail' by hand-held gamma probe", 1988. Second place winner, Ohio Chapter of the American College of Surgeons Resident Essay Contest, "The use of a hand-held gamma detector improves the safety of isolated limb perfusion", 1988. “The Spirit of Caring” Award, Ochsner Clinic, New Orleans, LA, 1991- 1993 Teacher of the Year and Outstanding Attending in General Surgery, 1996-97 by the Surgical House staff at St. Agnes Hospital. “Hands Humanitarian Award”, by the Hands Across America Organization in recognition of his voluntary treatment for children in need throughout America, Baltimore, Maryland. November 30,2001. Governor’s Citation of the State of Maryland for the successful mission in Hands Across America, Inc. November 30, 2001 Founder’s Award for the year 2003. This physician of the year award is given to the physician that has demonstrated performance as an exemplary physician during his years of service at St. Agnes HealthCare. The Daily Record, Healthcare Heroes Award for “Advancements in Healthcare.” Baltimore, Maryland March 28, 2007 2 “Premio Colombia Exterior A La Excelencia 2007.” This award was presented for excellence in science. Broadway, NY May 11, 2007 “Hispanic Hero” at the 3rd Annual Maryland Hispanic Youth Symposium. Baltimore, Maryland July 19, 2007 “Gold Star Caregiver Award.” Presented by The Sisters of Mercy in recognition of Gold Star Care performance and patient compliments. September 4, 2007 “Visitante Ilustre De Santiago De Cali.” Presented by the Mayor of City of Cali Colombia. February 26, 2008 Gobernador Citation Valle Del Cauca – Colombia for the contribution to improve the quality of life of the poorest and more vulnerable people. February 26, 2008 “La Medalla Santiago de Cali en el Grado Cruz de Oro.” Presented by Concejo Municipal of City of Cali Colombia February 29, 2008 “Hispanic Hero Award for Excellence as a Medical/Social Entrepreneur.” Presented by USHYEE. Baltimore, MD June 5, 2008 Honored by Baltimore Magazine as “Top Doctor” Baltimore, MD November 2009 “Gold Star Teamwork Award.” Presented by The Sisters of Mercy in recognition of Gold Star performance. December 2009 Honored by Baltimore Magazine as “Top Doctor” Baltimore, MD November 2011 Honored by Baltimore Magazine as “Top Doctor” Baltimore, MD November 2012 Honored by Fusionarte as one of “100 Colombianos” who represent the talent, creativity and perseverance of Colombia. Bogota, Colombia December 2012 Honored by Baltimore Magazine as “Top Doctor” Baltimore, MD November 2014 Recognized by Castle Connolly as a “Top Doctor” June 2016 Honored by Baltimore Magazine as “Top Doctor” Baltimore, MD November 2016 Recognized by Castle Connolly as a “Top Doctor” June 2017 Honored by Baltimore Magazine as “Top Doctor” Baltimore, MD November 2017 3 “Gold Star Caregiver Award.” Presented by The Sisters of Mercy, in recognition of Gold Star Care performance and patient compliments September 2018 Honored by Baltimore Magazine as “Top Doctor” Baltimore, MD November 2019 Honored by Baltimore Magazine as “Top Doctor” Baltimore, MD November 2020 MEDICAL ASSOCIATIONS: 1. American College of Surgeons 2. Society of Surgical Oncology 3. American Society of Clinical Oncology 4. The Society for Surgery of the Alimentary Tract 5. Medical and Chirurgical Faculty of Maryland 6. Southeastern Surgical Association 7. American Medical Association 8. Association of the Alumni of the "Division de Salud of the Universidad del Valle 9. National Cancer Institute - Clinical Investigator 10. American Society of Peritoneal Surface Malignancies, Chairperson, Mid-Atlantic Chapter 11. PMP Research Foundation 12. Peritoneal Surface Oncology Group International APPOINTMENTS: 1988-1993: Staff Surgical Oncology - General Surgery, Alton Ochsner Medical Foundation 1988-1993: Clinical Assistant Professor of Surgery, Tulane University Medical Center 1990-1993: Medical Director, Surgical Technology Program, Ochsner School of Allied Health Sciences 1991-1993: Louisiana District #1 Committee on Applicants of the American College of Surgeons 1993-1994: Founding Chief, Division of Surgical Oncology, Health Care International (Scotland) Ltd 1993-1994: Co-Director of Oncology Program, Health Care International (Scotland) Ltd. 1994-2006: Chief, Surgical Oncology, Saint Ages Health Care 1996-1997: Member, Editorial board of the Maryland Medical Journal (MMJ) 1997-1998: Member, Membership committee of the Society of Head and Neck Surgeons 1998-2006: Founding Medical Director, Clinical Research Center 2000-2003: Member, Editorial Board of Clinical Researcher 2003-present: Faculty and Preceptor, Ethicon Endosurgery Institute 4 2005-present: Member, Scientific Council of Colombia Médica- Universidad del Valle 2006-2011: Member, Scientific Review Committee, Mercy Medical Center 2006-present: Medical Director, Annual Colombia Medical Mission 2006-present: Director, The Institute for Cancer Care, Mercy Medical Center 2006-present: Chief, Surgical Oncology, Mercy Medical Center 2008-present: The Commission on Cancer’s Cancer Liaison Physician 2009-present: Member, Editorial Board of Colombia Médica - Universidad del Valle 2011-present: Founder and President, Partners for Cancer Care and Prevention/Fundación Prevención y Tratamiento del Cáncer en Cali-Colombia 2012-present: CTEP Investigator 2018-present: Member, ACPMP Research Foundation Professional Advisory Board HOSPITAL COMMITTEES: Ochsner Medical Institutions: 1989-1993: Oncology 1992-1993: Operating Room 1992-1993: Pre-Operative Testing Health Care International (Scotland),Ltd. 1993-1994: Oncology 1993-1994: Patient Education 1993-1994: Drug and Therapeutics 1993-1994: Clinical Systems Users St. Agnes HealthCare 1994-2006: Cancer Committee 1994-1997: Patient Education 1994-2006: Institutional Review Board 1998-2006: Clinical Research Board of Directors Mercy Medical Center 2006-present: Director, The Institute for Cancer Care 2006-present: Cancer Committee 2008-present: Cancer Liaison Physician CURRENT PROJECTS: 1. Sardi A Microbiologic and immune characteristics of peritoneal tissues in patients with appendiceal cancer with peritoneal spread. MMC 2010-31, 2010 to present 2. Sardi A. A study of tissue molecular markers and their relationship to treatment and outcome in appendiceal cancer with pseudomyxoma peritonei (PMP). MMC 2010-33, 2010 to present 3. Sardi A. Surgical oncology research database and tissue resource study. MMC 2010-37, 2010- present. 4. Sardi A., Diaz-Montes TM. A phase II randomized study: Outcomes after cytoreductive surgery (CRS) with or without carboplatin hyperthermic intraperitoneal chemotherapy (HIPEC) followed by 5 adjuvant chemotherapy as initial treatment of advanced stage (stage III/IV) ovarian, fallopian tube, and primary peritoneal cancer, NCT02124421, 2014 to present 5. Sardi A. Clinical trial to define the effect of perioperative H. Pylori eradication with antibiotic treatment on the long term outcomes of patients with pseudomyxoma peritonei of appendiceal origin undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC). NCT02387203, 2014 to present 6. Sardi A., Knight R. A cohort study of the gastrointestinal microbiome in appendiceal cancer with peritoneal spread. A case control, cohort study to determine whether the gut microbiome of participants with appendiceal tumors with peritoneal spread differs from a healthy, age-matched cohort. MMC 2015-53, 2105-present 7. Sardi A., Diaz-Montes TP. Clinical
Load more

Recommended publications
  • Hyperthermic Intrathoracic Chemotherapy for Malignant Pleural Mesothelioma: the Forefront of Surgery-Based Multimodality Treatment
    Journal of Clinical Medicine Review Hyperthermic Intrathoracic Chemotherapy for Malignant Pleural Mesothelioma: The Forefront of Surgery-Based Multimodality Treatment Vittorio Aprile 1,†, Alessandra Lenzini 1,†, Filippo Lococo 2, Diana Bacchin 1,* , Stylianos Korasidis 1, Maria Giovanna Mastromarino 1, Giovanni Guglielmi 3, Gerardo Palmiero 4, Marcello Carlo Ambrogi 1 and Marco Lucchi 1 1 Unit of Thoracic Surgery, Department of Critical Area and Surgical, Medical and Molecular Pathology, University of Pisa, 56122 Pisa, Italy; [email protected] (V.A.); [email protected] (A.L.); [email protected] (S.K.); [email protected] (M.G.M.); [email protected] (M.C.A.); [email protected] (M.L.) 2 Thoracic Surgery Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy; fi[email protected] 3 Occupational Health Department, U.O. Medicina Preventiva del Lavoro, Azienda Ospedaliero-Universitaria Pisana, 56122 Pisa, Italy; [email protected] 4 Pneumology Unit, Versilia Hospital, 55049 Camaiore, Italy; [email protected] * Correspondence: [email protected]; Tel.: +39-0-5099-5230 † These authors contributed equally to this work. Abstract: Introduction: Malignant Pleural Mesothelioma (MPM) is characterized by an aggressive Citation: Aprile, V.; Lenzini, A.; behavior and an inevitably fatal prognosis, whose treatment is still far from being standardized. The Lococo, F.; Bacchin, D.; Korasidis, S.; role of surgery is questionable since a radical resection is unattainable in most cases. Hyperthermic Mastromarino, M.G.; Guglielmi, G.; IntraTHOracic Chemotherapy (HITHOC) combines the advantages of antitumoral effects together Palmiero, G.; Ambrogi, M.C.; Lucchi, with those of high temperature on the exposed tissues with the aim to improve surgical radicality.
    [Show full text]
  • USAN Naming Guidelines for Monoclonal Antibodies |
    Monoclonal Antibodies In October 2008, the International Nonproprietary Name (INN) Working Group Meeting on Nomenclature for Monoclonal Antibodies (mAb) met to review and streamline the monoclonal antibody nomenclature scheme. Based on the group's recommendations and further discussions, the INN Experts published changes to the monoclonal antibody nomenclature scheme. In 2011, the INN Experts published an updated "International Nonproprietary Names (INN) for Biological and Biotechnological Substances—A Review" (PDF) with revisions to the monoclonal antibody nomenclature scheme language. The USAN Council has modified its own scheme to facilitate international harmonization. This page outlines the updated scheme and supersedes previous schemes. It also explains policies regarding post-translational modifications and the use of 2-word names. The council has no plans to retroactively change names already coined. They believe that changing names of monoclonal antibodies would confuse physicians, other health care professionals and patients. Manufacturers should be aware that nomenclature practices are continually evolving. Consequently, further updates may occur any time the council believes changes are necessary. Changes to the monoclonal antibody nomenclature scheme, however, should be carefully considered and implemented only when necessary. Elements of a Name The suffix "-mab" is used for monoclonal antibodies, antibody fragments and radiolabeled antibodies. For polyclonal mixtures of antibodies, "-pab" is used. The -pab suffix applies to polyclonal pools of recombinant monoclonal antibodies, as opposed to polyclonal antibody preparations isolated from blood. It differentiates polyclonal antibodies from individual monoclonal antibodies named with -mab. Sequence of Stems and Infixes The order for combining the key elements of a monoclonal antibody name is as follows: 1.
    [Show full text]
  • Pseudo-Pseudomyxoma Peritonei from Peritoneal Sarcomatosis
    http://crcp.sciedupress.com Case Reports in Clinical Pathology, 2015, Vol. 2, No. 4 CASE REPORT Pseudo-pseudomyxoma peritonei from peritoneal sarcomatosis Shuja Ahmed1, Ling Guo2, Shadi A. Qasem2, Edward A. Levine1 1. Surgical Oncology Service, Department of General Surgery, Wake Forest University School of Medicine, Winston Salem, NC, USA. 2. Department of Pathology, Wake Forest University School of Medicine, Winston Salem, NC, USA. Correspondence: Edward A. Levine, MD. Address: Surgical Oncology Service, Medical Center Blvd, Winston-Salem, North Carolina, USA. E-mail: [email protected] Received: February 12, 2015 Accepted: April 12, 2015 Online Published: June 3, 2015 DOI: 10.5430/crcp.v2n4p14 URL: http://dx.doi.org/10.5430/crcp.v2n4p14 Abstract Background: Pseudomyxoma peritonei (PMP) is a rare clinical entity of mucinous ascites, most commonly associated with appendiceal mucinous neoplasms. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) remains the current standard of care for PMP. Peritoneal sarcomatosis (PS) is an exceptionally rare disease with a poor prognosis. PMP associated with PS has not been previously described. The role of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for PS with or without PMP is not well-defined. PS manifesting like PMP has not been previously described. Case presentation: A 74-year-old patient with several weeks history of vague abdominal pain and increased abdominal girth was referred to our facility after incidental finding of PMP during laparoscopic inguinal hernia repair. After complete work-up, he was advised to undergo CRS/HIPEC. Intra-operatively, he was noted to have extensive mucinous ascites and underwent aggressive CRS and HIPEC Result: Final pathology revealed myxoid liposarcoma with associated intraperitoneal mucin dissemination, which was confirmed with cytogenetic analysis.
    [Show full text]
  • Monoclonal Antibody Playbook
    Federal Response to COVID-19: Monoclonal Antibody Clinical Implementation Guide Outpatient administration guide for healthcare providers 2 SEPTEMBER 2021 1 Introduction to COVID-19 Monoclonal Antibody Therapy 2 Overview of Emergency Use Authorizations 3 Site and Patient Logistics Site preparation Patient pathways to monoclonal administration 4 Team Roles and Responsibilities Leadership Administrative Clinical Table of 5 Monoclonal Antibody Indications and Administration Indications Contents Preparation Administration Response to adverse events 6 Supplies and Resources Infrastructure Administrative Patient Intake Administration 7 Examples: Sites of Administration and Staffing Patterns 8 Additional Resources 1 1. Introduction to Monoclonal Therapy 2 As of 08/13/21 Summary of COVID-19 Therapeutics 1 • No Illness . Health, no infections • Exposed Asymptomatic Infected . Scope of this Implementation Guide . Not hospitalized, no limitations . Monoclonal Antibodies for post-exposure prophylaxis (Casirivimab + Imdevimab (RGN)) – EUA Issued. • Early Symptomatic . Scope of this Implementation Guide . Not hospitalized, with limitations . Monoclonal Antibodies for treatment (EUA issued): Bamlanivimab + Etesevimab1 (Lilly) Casirivimab + Imdevimab (RGN) Sotrovimab (GSK/Vir) • Hospital Adminission. Treated with Remdesivir (FDA Approved) or Tocilizumab (EUA Issued) . Hospitalized, no acute medical problems . Hospitalized, not on oxygen . Hospitlaized, on oxygen • ICU Admission . Hospitalized, high flow oxygen, non-invasive ventilation
    [Show full text]
  • Appendix Cancer and Pseudomyxoma Peritonei (PMP) a Guide for People Affected by Cancer
    Cancer information fact sheet Understanding Appendix Cancer and Pseudomyxoma Peritonei (PMP) A guide for people affected by cancer This fact sheet has been prepared What is appendix cancer? to help you understand more about Appendix cancer occurs when cells in the appendix appendix cancer and pseudomyxoma become abnormal and keep growing and form a peritonei (PMP). mass or lump called a tumour. Many people look for support after The type of cancer is defined by the particular being diagnosed with a cancer that cells that are affected and can be benign (non- is rare or less common than other cancerous) or malignant (cancerous). Malignant cancer types. This fact sheet includes tumours have the potential to spread to other information about how these cancers parts of the body through the blood stream or are diagnosed and treated, as well as lymph vessels and form another tumour at a where to go for additional information new site. This new tumour is known as secondary and support services. cancer or metastasis. Many people feel shocked and upset when told they have cancer. You may experience strong emotions The abdomen after a cancer diagnosis, especially if your cancer is rare or less common like appendix cancer or PMP. A feeling of being alone is usual with rare cancers, and you might be worried about how much is known about your type of cancer as well as how it will be managed. You may also be concerned about the cancer coming back after treatment. Linking into local support services (see last page) can help overcome feelings of isolation and will give you information that you may find useful.
    [Show full text]
  • Pleural and Peritoneal Cavities 95
    94 Maher, Daly Management of bleomycin lung toxicity is immunosuppressive and known steroid spar- frequently difficult, though steroids are wide- ing effects. ly recommended and evidence supporting We believe that all patients with bleomycin their role comes from both animal studies6 lung toxicity should receive a trial of cortico- Thorax: first published as 10.1136/thx.48.1.94 on 1 January 1993. Downloaded from and clinical reports on a few patients.5 steroids. The dose used should depend on the Less settled, however, is the value of these severity of the pneumonitis. agents in advanced bleomycin lung toxicity. Samuels and coworkers7 described a series of 1 Umezawa H, Maeda K, Takeuchi T, Okami Y. New five such patients, all of whom received pred- antibiotics, bleomycin A and B. Journal of Antibiotics (Tokyo) 1966;19:200-9. nisolone in doses of 60-100 mg daily. All five 2 Kuo MT, Haidle CW. Characterization of chain breakage died of acute respiratory failure despite this in DNA induced by bleomycin. Biochem Biophys Acta 1974;335:109-14. treatment. Gilson and Sahn8 reported a 3 Chandler DB. Possible mechanisms of bleomycin-induced patient with bleomycin lung toxicity who fibrosis. In: Cooper J Allen D, ed. Clinics in chest medi- cine. Philadelphia: Saunders, 1990:21-30. developed the adult respiratory distress syn- 4 Holoye PY, Luna MA, Mackay B, Bedrossian CWM. drome after surgery and ultimately responded Bleomycin hypersensitivity pneumonitis. Ann Intern Med 1978; 88:47-9. to a combination of antibiotics and methyl- 5 Jules-Elysee K, White DA. Bleomycin-induced pulmonary prednisolone 500 mg a day.
    [Show full text]
  • REGENERON PHARMACEUTICALS, INC. (Exact Name of Registrant As Specified in Charter)
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 9, 2017 (February 9, 2017) REGENERON PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) New York 000-19034 13-3444607 (State or other jurisdiction (Commission (IRS Employer of Incorporation) File No.) Identification No.) 777 Old Saw Mill River Road, Tarrytown, New York 10591-6707 (Address of principal executive offices, including zip code) (914) 847-7000 (Registrant's telephone number, including area code) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Item 2.02 Results of Operations and Financial Condition. On February 9, 2017, Regeneron Pharmaceuticals, Inc. issued a press release announcing its financial and operating results for the quarter and year ended December 31, 2016. A copy of the press release is being furnished to the Securities and Exchange Commission as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference to this Item 2.02.
    [Show full text]
  • The Future of Antibodies As Cancer Drugs
    REVIEWS Drug Discovery Today Volume 17, Numbers 17/18 September 2012 The biopharmaceutical industry’s pipeline of anticancer antibodies includes 165 candidates with substantial diversity in composition, targets and mechanisms of action that hold promise to be the cancer drugs of the future. Reviews FOUNDATION REVIEW Foundation review: The future of antibodies as cancer drugs 1 2 Dr Janice Reichert Janice M. Reichert and Eugen Dhimolea is Research Assistant Professor at Tufts 1 Center for the Study of Drug Development, Tufts University School of Medicine, 75 Kneeland Street, University’s Center for the Study of Drug Development Suite 1100, Boston, MA 02111, USA 2 (CSDD). She is also Founder Department of Medical Oncology, Dana-Farber Cancer Institute/Harvard Medical School, 77 Louis Pasteur Ave., and Editor-in-Chief of mAbs, Harvard Institutes of Medicine, Room 309, Boston, MA 02215, USA a peer-reviewed, PubMed- indexed biomedical journal that focuses on topics relevant to antibody research Targeted therapeutics such as monoclonal antibodies (mAbs) have proven and development; President of the board of directors of The Antibody Society; and a member of the board successful as cancer drugs. To profile products that could be marketed in of the Peptide Therapeutics Foundation. At CSDD, the future, we examined the current commercial clinical pipeline of mAb Dr Reichert studies innovation in the pharmaceutical and biotechnology industries. Her work focuses on candidates for cancer. Our analysis revealed trends toward development of strategic analyses of investigational candidates and marketed products, with an emphasis on the clinical a variety of noncanonical mAbs, including antibody–drug conjugates development and approval of new therapeutics and (ADCs), bispecific antibodies, engineered antibodies and antibody vaccines.
    [Show full text]
  • CYRAMZA (Ramucirumab) Injection Label
    1 HIGHLIGHTS OF PRESCRIBING INFORMATION • 500 mg/50 mL (10 mg per mL) solution, single-dose vial (3) These highlights do not include all the information needed to use CYRAMZA safely and effectively. See full prescribing information ------------------------------- CONTRAINDICATIONS ------------------------------ for CYRAMZA. None CYRAMZA (ramucirumab) injection, for intravenous infusion ------------------------ WARNINGS AND PRECAUTIONS ----------------------- Initial U.S. Approval: 2014 • Arterial Thromboembolic Events (ATEs): Serious, sometimes fatal WARNING: HEMORRHAGE ATEs have been reported in clinical trials. Discontinue CYRAMZA for severe ATEs. (5.2) See full prescribing information for complete boxed warning. • Hypertension: Monitor blood pressure and treat hypertension. CYRAMZA increased the risk of hemorrhage, including severe Temporarily suspend CYRAMZA for severe hypertension. and sometimes fatal hemorrhagic events. Permanently Discontinue CYRAMZA for hypertension that cannot be medically discontinue CYRAMZA in patients who experience severe controlled. (5.3) bleeding [see Dosage and Administration (2.3), Warnings and • Infusion-Related Reactions: Monitor for signs and symptoms Precautions (5.1)]. during infusion. (5.4) • Gastrointestinal Perforation: Discontinue CYRAMZA. (5.5) --------------------------- RECENT MAJOR CHANGES -------------------------- • Impaired Wound Healing: Withhold CYRAMZA prior to surgery. Indications and Usage 11/2014 (5.6) • Clinical Deterioration in Patients with Cirrhosis: New onset or Dosage and Administration:
    [Show full text]
  • COVID-19 Immunotherapy: Novel Humanized 47D11 Monoclonal Antibody
    Review Article ISSN: 2574 -1241 DOI: 10.26717/BJSTR.2020.29.004828 COVID-19 Immunotherapy: Novel Humanized 47D11 Monoclonal Antibody Basma H Marghani* Department of Physiology, Faculty of Veterinary Medicine, Mansoura University, Egypt *Corresponding author: Basma H Marghani, Department of Physiology, Faculty of Veterinary Medicine, Mansoura University, Egypt ARTICLE INFO ABSTRACT Received: August 10, 2020 Published: August 18, 2020 rapidly to the other countries all over the world, caused a novel Coronavirus-2019 (COV- SARS-CoV-2 was appeared firstly in Wuhan, China in December 2019, then spread- gency. After infection, virus entry the host cell through spike proteins (S)- angiotensin Citation: Basma H Marghani. COVID-19 ID-19). The World Health Organization was branded COVID-19 as a global health emer Immunotherapy: Novel Humanized 47D11 converting enzyme 2 (ACE2) cell membrane receptor via their S-Binding domain, then Monoclonal Antibody. Biomed J Sci & Tech virus replication caused acute respiratory disease syndrome (ARDS). Till now there was Res 29(4)-2020. BJSTR. MS.ID.004828. no vaccines or anti-viral drugs for coronavirus infection. One effective treatment is the use of human monoclonal antibodies (mAbs) which are engineered to target and block Keywords: COVID-19; Immunotherapy; cell surface receptor. mAbs could be given to people in the early stages of COVID-19 as a Full-Length Humanized Monoclonal Anti- therapeutic, or used prophylactically to give immediate, long-term immunity to vulnera- bodies; ACE Inhibitor ble people such as healthcare workers. The neutralizing humanized 47D11 monoclonal antibody targets a common epitope on SARS-CoV2 virus and may offer potential for pre- Abbreviations: ACE2: Angiotensin-Con- vention and treatment of COVID-19.89U (Graphical Abstract 1).
    [Show full text]
  • Ovarian Carcinomas, Including Secondary Tumors: Diagnostically Challenging Areas
    Modern Pathology (2005) 18, S99–S111 & 2005 USCAP, Inc All rights reserved 0893-3952/05 $30.00 www.modernpathology.org Ovarian carcinomas, including secondary tumors: diagnostically challenging areas Jaime Prat Department of Pathology, Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona, Spain The differential diagnosis of ovarian carcinomas, including secondary tumors, remains a challenging task. Mucinous carcinomas of the ovary are rare and can be easily confused with metastatic mucinous carcinomas that may present clinically as a primary ovarian tumor. Most of these originate in the gastrointestinal tract and pancreas. International Federation of Gynecology and Obstetrics (FIGO) stage is the single most important prognostic factor, and stage I carcinomas have an excellent prognosis; FIGO stage is largely related to the histologic features of the ovarian tumors. Infiltrative stromal invasion proved to be biologically more aggressive than expansile invasion. Metastatic colon cancer is frequent and often simulates ovarian endometrioid adenocarcinoma. Although immunostains for cytokeratins 7 and 20 can be helpful in the differential diagnosis, they should always be interpreted in the light of all clinical information. Occasionally, endometrioid carcinomas may exhibit a microglandular pattern simulating sex cord-stromal tumors. However, typical endometrioid glands, squamous differentiation, or an adenofibroma component are each present in 75% of these tumors whereas immunostains for calretinin and alpha-inhibin are negative. Endometrioid carcinoma of the ovary is associated in 15–20% of the cases with carcinoma of the endometrium. Most of these tumors have a favorable outcome and they most likely represent independent primary carcinomas arising as a result of a Mu¨ llerian field effect.
    [Show full text]
  • Governor Thomas H. Kean Collection, 1894-1994 (Bulk: 1982-1989) Finding Aid
    Governor Thomas H. Kean Collection, 1894-1994 (Bulk: 1982-1989) Finding Aid Drew University Archives 36 Madison Avenue Madison, NJ 07940 Phone: 973-408-3532 Fax: 973-408-3770 http://www.drew.edu/library/special-collections Governor Thomas H. Kean Collection, 1894-1994 (Bulk: 1982-1989) Finding Aid, Page 1 Drew University Summary Information Creator(s) Kean, Thomas H. Title and dates Governor Thomas H. Kean Collection, 1894-1994 (Bulk: 1982-1989) Abstract The Governor Thomas H. Kean collection broadly consists of the records created during the governor's two terms of office in New Jersey, from 1982-1990. Included are the full run of his legislative briefing binders, records from trips and conferences, typescript copies of speeches, photographs, correspondence, office files, material on the issue of education, press releases and news clippings, and related records. A small percentage of the records were created in the 1990s during Kean's presidency of Drew University. Size 156 linear feet (125 boxes) Location United Methodist Archives and Research Center Madison, NJ Language of materials English. Biography of Governor Thomas H. Kean Thomas H. Kean was born on April 21, 1935. Kean received his B.A. degree from Princeton University and his M.A. from Columbia University Teachers College. He taught private school in Massachusetts before entering politics. Kean was a member of the New Jersey Assembly from1968-1977. He was elected governor of New Jersey in 1982. As Governor, Kean was rated among America's five most effective state leaders by Newsweek magazine; noted for tax cuts that spurred 750,000 new jobs; a federally replicated welfare reform program; landmark environmental policies, and over 30 education reforms.
    [Show full text]